We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Things haven’t gone Alexion’s way lately: After investors cheered the possibility of an Amgen merger, the hoped-for partner advanced its Soliris patent challenge.